Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Clear cell renal cell carcinomas (ccRCCs) frequently have mutations in epigenetic modifiers like SETD2.
• SETD2 is responsible for writing the H3K36me3 mark, crucial for gene regulation.
• DNA methylation (5mC) is therapeutically targetable and linked to H3K36me3.

Purpose of the Study:

• To investigate the genome-wide DNA methylation patterns in models of SETD2 inactivation.
• To understand how SETD2 mutations affect DNA methylation and gene expression in ccRCCs and other cancers.

Main Methods:

• Profiling DNA methylation (5mC) in SETD2-depleted cell lines and SETD2 mutant primary tumors.
• Analyzing H3K36me3 patterns and gene expression changes in relation to DNA methylation.
• Correlating epigenetic alterations with tumor type, SETD2 genotype, and grade.

Main Results:

• SETD2 inactivation led to genome-wide DNA hypermethylation, particularly at intergenic regions near low-expressing genes.
• Ectopic H3K36me3 gains were observed at hypermethylated regions, correlating with gene upregulation.
• Poised enhancers of developmental genes were identified as key hypermethylation targets.
• SETD2 mutant ccRCCs, papillary renal cell carcinomas, and lung adenocarcinomas showed DNA hypermethylation that segregated tumors by genotype and grade.

Conclusions:

• SETD2 mutations drive tumorigenesis through coordinated disruption of the epigenome and transcriptome.
• These findings highlight the role of epigenetic dysregulation in cancer development.
• Implications for developing novel therapeutic strategies targeting chromatin regulator mutant tumors.